Conv. Plasma
Nigella Sativa
Peg.. Lambda

All convalescent plasma..
Meta analysis
Home COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -7% Improvement Relative Risk Combined death at 28 d.. -7% Ventilation 1% Viral clearance 28% Conv. Plasma  PLACID  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 464 patients in India (April - July 2020) Improved viral clearance with convalescent plasma (p=0.02) Agarwal et al., BMJ, October 2020 Favors conv. plasma Favors control

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Agarwal et al., BMJ, doi:10.1136/bmj.m3939, PLACID, CTRI/2020/04/024775
Oct 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 464 hospitalized patients in India, 235 treated with convalescent plasma, showing no improvement in combined death at 28 days or progression to severe disease.
risk of death, 7.0% higher, RR 1.07, p = 0.74, treatment 34 of 235 (14.5%), control 31 of 229 (13.5%).
combined death at 28 days or progression to severe disease, 7.0% higher, RR 1.07, p = 0.74, treatment 44 of 235 (18.7%), control 41 of 229 (17.9%).
risk of mechanical ventilation, 1.0% lower, RR 0.99, p = 0.98, treatment 19 of 227 (8.4%), control 19 of 224 (8.5%), NNT 892.
risk of no viral clearance, 28.0% lower, RR 0.72, p = 0.02, treatment 56 of 173 (32.4%), control 76 of 169 (45.0%), NNT 7.9, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Agarwal et al., 22 Oct 2020, Randomized Controlled Trial, India, peer-reviewed, 6 authors, study period 22 April, 2020 - 14 July, 2020, average treatment delay 8.0 days, trial CTRI/2020/04/024775 (PLACID).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Anup Agarwal, Aparna Mukherjee, Gunjan Kumar, Pranab Chatterjee, Tarun Bhatnagar, Pankaj Malhotra
BMJ, doi:10.1136/bmj.m3939
OBJECTIVE To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India. DESIGN Open label, parallel arm, phase II, multicentre, randomised controlled trial. SETTING 39 public and private hospitals across India. PARTICIPANTS 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm). INTERVENTIONS Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study. MAIN OUTCOME MEASURE Composite of progression to severe disease (PaO 2 / FiO 2 <100 mm Hg) or all cause mortality at 28 days post-enrolment. RESULTS Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54). CONCLUSION Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19.
Supplementary information: Additional tables and figures Supplementary information: Detailed list of PLACID Trial collaborators
Abolghasemi, Eshghi, Cheraghali, Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study, Transfus Apher Sci, doi:10.1016/j.transci.2020.102875
Bl, Samk, Vr, As, Pb et al., Patient enrolment, conduct of study, clinical care and data collection: Madras Medical College
Casadevall, Joyner, Pirofski, SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy, J Clin Invest, doi:10.1172/JCI139760
Cheng, Wong, Soo, Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-004-1271-9
Devasenapathy, Ye, Loeb, Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and metaanalysis, CMAJ, doi:10.1503/cmaj.200642
Edwards, Aronson, Adverse drug reactions: definitions, diagnosis, and management, Lancet, doi:10.1016/S0140-6736(00)02799-9
Epstein, Burnouf, Points to consider in the preparation and transfusion of COVID-19 convalescent plasma, Vox Sang, doi:10.1111/vox.12939
Ford, Pragmatic Trials, N Engl J Med, doi:10.1056/NEJMra1510059
Gharbharan, Jordans, Kessel, Convalescent Plasma for COVID-19. A randomized clinical trial, medRxiv
Hegerova, Gooley, Sweerus, Use of convalescent plasma in hospitalized patients with COVID-19: case series, Blood, doi:10.1182/blood.2020006964
Joyner, Bruno, Klassen, Safety Update: COVID-19 Convalescent Plasma in 20 000 Hospitalized Patients, Mayo Clin Proc
Joyner, Senefeld, Klassen, Effect of convalescent plasma on mortality among hospitalized patients with covid-19: initial three-month experience, doi:10.1101/2020.08.12.20169359v1.full.pdf
Khan, Hizbullah, Jain, Coronavirus pandemic fuels blackmarket for plasma of recovered patients, India Today
Li, Zhang, Hu, Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.10044
Long, Tang, Shi, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nat Med, doi:10.1038/s41591-020-0965-6
Luke, Casadevall, Watowich, Hoffman, Beigel et al., Hark back: passive immunotherapy for influenza and other serious infections, Crit Care Med, doi:10.1097/CCM.0b013e3181d44c1e
Mm ;, Gk, Pc, Tb, Sd et al., Data Management Team: KK, RS. Generation of randomisation sequence: VSK. Central Implementation Team: AA, AM, GK, AT. Laboratory Analysis Team
Norton, Miller, Kleinman, Computing adjusted risk ratios and risk differences in Stata, Stata J, doi:10.1177/1536867X1301300304
Piechotta, Chai, Valk, Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database Syst Rev
Robbiani, Gaebler, Muecksch, Convergent antibody responses to SARS-CoV-2 in convalescent individuals, Nature, doi:10.1038/s41586-020-2456-9
Rojas, Rodríguez, Monsalve, Convalescent plasma in Covid-19: Possible mechanisms of action, Autoimmun Rev, doi:10.1016/j.autrev.2020.102554
Sarkale, Patil, Yadav, First isolation of SARS-CoV-2 from clinical samples in India, Indian J Med Res
Shen, Wang, Zhao, Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma, JAMA, doi:10.1001/jama.2020.4783
Van Griensven, Edwards, De Lamballerie, Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N Engl J Med, doi:10.1056/NEJMoa1511812
Wu, Wang, Liu, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications, medRxiv
Xia, Li, Wu, Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion, Blood, doi:10.1182/blood.2020007079
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop